Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
About Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
18
Amgen
2
EMD Serono Research & Development Institute, Inc.
2
Cellectar Biosciences, Inc.
1
Gemin X
1
Nektar Therapeutics
1
OSE Immunotherapeutics
1
OSI Pharmaceuticals
1
Pfizer
1
Puma Biotechnology, Inc.
1
Samsung Bioepis Co., Ltd.
1
Clinical Trials at Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
During the past decade, Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 13 clinical trials were completed, i.e. on
average, 59.1% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 4 clinical trials were completed. i.e. 50%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
2005-12-01
2009-01-01
Completed
172
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
2006-11-01
2010-02-01
Completed
903
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
2006-09-01
2014-06-01
Completed
1,252
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
2008-05-01
2011-11-01
Completed
218
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
2011-06-16
2015-09-14
Completed
878
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
2012-04-01
2016-07-01
Terminated
222
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
2013-04-01
2015-12-01
Terminated
696
A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
2013-08-06
2018-09-06
Completed
287
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" #1 sponsor was "Hoffmann-La Roche" with 18 trials, followed by "Amgen" with 2 trials
sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "Cellectar Biosciences, Inc." with 1 trials sponsored and "Gemin X"
with 1 trials sponsored. Other sponsors include 4 different institutions and
companies that sponsored additional 14 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii"
#1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Cephalon" with 1 trials as a collaborator, "Exelixis" with 1 trials as a collaborator and "Jazz Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
According to Clinical.Site data, the most researched conditions in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" are
"Non-Small Cell Lung Cancer" (9 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Non Small Cell Lung Cancer" (3 trials), "Non-small Cell Lung Cancer" (3 trials) and "Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" in a lesser frequency.
Clinical Trials Intervention Types at Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
Most popular intervention types in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" are "Drug" (33 trials) and "Biological" (2 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (13 trials), "Carboplatin" (9 trials), "Docetaxel" (9 trials), "Gemcitabine" (5 trials) and "Pemetrexed" (5 trials). Other intervention names were less common.
Clinical Trials Genders at Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
The vast majority of trials in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii" are
33 trials for "All" genders.
Clinical Trials Status at Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
Currently, there are NaN active trials in "Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii".
undefined are not yet recruiting,
8 are recruiting,
7 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 15 completed trials in Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, 3 "Phase 1"
clinical trials were conducted, 10 "Phase 2" clinical
trials and 22 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 0 trials that are defined as “Not Applicable".